TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study (Xenograft)
Head and Neck Squamous Cell Carcinoma
About this trial
This is an interventional supportive care trial for Head and Neck Squamous Cell Carcinoma focused on measuring Head and neck cancer, Patient derived Xenograft, Chemotherapy, Metastases
Eligibility Criteria
Inclusion Criteria:
- Patients with recurrent metastatic squamous cell carcinoma of the head and neck.
- Lesion amenable to biopsy (1 cm or more)
- Lesion capable of yielding 4 biopsy cores
- 18 years or older
- Capable of providing and signing for informed consent
Exclusion Criteria:
- Cognitive impairment prohibitive to providing informed consent
- Pregnant or lactating women.
Sites / Locations
- London Regional Cancer Program
Arms of the Study
Arm 1
Arm 2
Other
Other
HNSCC -PDX development
RMHNSCC -PDX drug testing
Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.